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PCV35 PHARMACOECONOMIC MODEL OF ENOXAPARIN VERSUS HEPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN MEDICAL PATIENTS
Milani-Jr R J 1 , Follador W 2 , Gonçalves J 2 , Di Sena V 2 1 São Paulo University, São Paulo, São Paulo, Brazil, 2 Sanofi -Aventis, São Paulo, São Paulo, Brazil OBJECTIVES: Venous thromboembolism (VTE) causes signifi cant morbidity and mortality and represents a huge health economic burden. Although enoxaparin has some advantages over unfractioned heparin (UFH), both are recommended for prophylaxis of VTE according to the guidelines from the Brazilian Medical Association. We present a tool to aid in selecting among similarly effective agents for VTE prophylaxis. The costs of UFH and enoxaparin to prevent venous thromboembolism in medical patients in the Brazilian treatment environment were compared. METHODS: A decision model was used in a pharmacoeconomic comparison of enoxaparin and UFH, each given for seven days, for the prophylaxis of VTE in medical patients. In the model four main outcome pathways could follow prophylaxis: major bleeding, proximal deep venous thrombosis (with or without pulmonary embolism), distal deep venous thrombosis (DVT), and no DVT. False-negative or false-positive clinical diagnoses of VTE were also taken into account. Probabilities of thromboembolic events and major bleeding were derived from published randomized clinical trials and metaanalysis. Costs were calculated using the microcosting technique and the administrative health care claims database of a major Brazilian Health Maintenance Organization from July, 2007 to June, 2008 . The claims represented a full range of health plans levels at different hospitals. Only the costs related to the VTE prophylaxis and adverse events, acute VTE diagnosis, treatment and complications were considered. RESULTS: Enoxaparin dominated UFH. There were cost savings of 74,121 Brazilians reais per 1,000 patients by using enoxaparin instead of UFH for prophylaxis of VTE. The base-case analysis also demonstrated that the extra costs in the UFH group were mainly related to the management of hemorrhagic adverse events. CONCLUSIONS: This model of enoxaparin versus UFH for VTE prophylaxis in medical patients showed that enoxaparin was less costly than UFH in overall expected costs from the hospital perspective.
PCV36 THE IMPACT OF A STATIN FORMULARY CHANGE ON HEALTH OUTCOMES AND MEDICAL COSTS
Vlahiotis A 1 , Cox E 2 1 Express Scripts, Inc., Saint Louis, MO, USA, 2 Express Scripts, Inc., Maryland Heights, MO, USA OBJECTIVES: To determine the effect of a formulary change in the statin drug class on health outcomes and disease-specifi c health care costs. METHODS: A retrospective cohort design was implemented using pharmacy and medical claims data from a large national employer group. Patients (n 330)with one or more claims for atorvastatin or another statin during the six months prior to a formulary change on January 1, 2006 were identifi ed and evaluated. The formulary change was implemented for all patients however, only those patients taking atorvastatin were affected. Cardiacrelated medical events (tests, doctor visits, outpatient facility visits, and acute cardiovascular events) and disease-specifi c costs during the year following the formulary change were measured. The impact of formulary change on cardiac-related medical events and disease-specifi c costs were evaluated using multivariate analysis controlling for gender, age, comorbidity status, and drug indication (primary vs. secondary prevention). RESULTS: Of the 330 patients, 180 (55%) used atorvastatin prior to the formulary change. After the implementation of the formulary change, 146 (81%) of patients switched to a preferred statin drug, 19 (10%) discontinued statin therapy, and 16 (9%) continued taking atorvastatin as a non-preferred drug. There were no signifi cant differences in the proportions of patients with cardiac tests (p 0.70), doctor's visits (p 0.64), outpatient facility visits (p 0.52), or acute cardiovascular events (p 0.13) in the year after the formulary change between patients with preformulary change claims for atorvastatin or another statin. There were no statistically signifi cant differences in health care costs among patients with pre-formulary change claims for atorvastatin or another statin after adjustment for covariates (OR 0.89, 95% CI: 0.41-1.92). CONCLUSIONS: Changing the formulary status of atorvastatin does not appear to adversely affect the total medical costs or utilization of cardiacrelated health care services.
PCV37 ECONOMIC IMPACT OF EDARAVONE THERAPY FOR PATIENTS WITH LACUNAR INFARCTION IN JAPAN
Inoue S 1 , Okuda S 2 , Yamaguchi T 3 1 Crecon Research and Consulting Inc, Shibuya-ku, Tokyo, Japan, 2 National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan, 3 National Cardiovascular Center, Suita, Osaka, Japan OBJECTIVES: Edaravone (Radicut ), which was fi rst approved in Japan in June 2001 as a free radical scavenger, is used widely for the treatment of acute ischemic stroke in Japan. The purpose of this study was to estimate the economic impact of edaravone therapy in Japan based on results of a meta-analysis of edaravone therapy for patients with lacunar infarction. METHODS: Japanese patients with lacunar infarction aged 35 years or older were included in this analysis. We compared the economic impact of treatment for lacunar infarction between the edaravone group (E group) and the non-edaravone group (non-E group). For the basic information on patient status for this analysis, we used previously published meta-analysis data on the modifi ed Rankin Scale (mRS) distribution 1 month or more after the occurrence of lacunar infarction. Four types of costs were considered: hospitalization costs for lacunar infarction therapy, nursing-care costs after hospital discharge, and productivity costs during hospitalization and due to work loss. RESULTS: The total costs per patient with lacunar infarction in the E and non-E groups were US$42,054 (1US$ 92 JPY) and US$47,270, respectively, and the potential cost savings for using edaravone therapy was estimated at US$5,216. The breakdown of total costs in the E and non-E groups, respectively were for hospitalization costs: US$10,215 (24.3%), and US$8,150 (17.2%), nursing-care costs: US$14,779 (35.1%), and US$18,256 (38.6%), decreased productivity costs due to hospitalization: US$1,956 (4.7%), and US$2,065 (4.4%), and those due to work loss: US$15,105 (35.9%), and US$18,691 (39.5%). CONCLU-SIONS: In this analysis, edaravone therapy for patients with lacunar infarction was ultimately a promising cost saving therapy compared with other therapies that did not use edaravone, as it avoided nursing-care costs and productivity loss despite being more expensive during acute treatment.
PCV38 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PROPHYLAXIS AFTER TOTAL HIP OR TOTAL KNEE REPLACEMENT IN KOREA
Kim J J 1 , Pollock R 2 , Jung S 3 , Diamantopoulos A 4 , Lees M 5 1 IMS Health, Seoul, South Korea, 2 IMS Health, Basel, Switzerland, 3 Bayer Korea, Seoul, South Korea, 4 IMS Health, London, UK, 5 Bayer HealthCare, Uxbridge, UK OBJECTIVES: To assess the cost-effectiveness of oral rivaroxaban versus subcutaneous enoxaparin for prevention of venous thromboembolism (VTE) following total hip replacement (THR) or total knee replacement (TKR) in Korea. METHODS: An economic model was developed to evaluate the clinical and economic consequences of rivaroxaban versus enoxaparin, based on the RECORD2 and 3 randomized controlled trials. RECORD2 compared a 35-day course of rivaroxaban with a 12-day course of enoxaparin in THR, while RECORD3 compared 12-day courses of rivaroxaban and enoxaparin following TKR. In RECORD2, rivaroxaban reduced total VTE (composite: any deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality) by 79% and symptomatic VTE by 80% versus 12-day enoxaparin. In RECORD3, rivaroxaban reduced total VTE by 49% and symptomatic VTE by 66% versus enoxaparin. Occurrence of major bleeding was similar with both agents. The model accounted resource use according to primary research data and included direct medical costs from the Korean Health Insurance Review Agency. Utilities were derived from published literature and clinical and economic outcomes were discounted at a 5% annual rate in line with Korean guidelines. The model reported effectiveness outcomes in quality-adjusted life years (QALYs) and costs in Korean Won (KRW) and was run over a fi ve-year time horizon. RESULTS: In THR, rivaroxaban demonstrated perpatient cost savings of KRW 40,803 versus enoxaparin and a gain of 0.0027 QALYs per patient. In TKR, rivaroxaban reduced per-patient costs by KRW 27,692 and resulted in a gain of 0.0019 QALYs per patient. Cost savings in the rivaroxaban arm
